Iambic Therapeutics, Inc. IAM
As ofNov 20, 2026, 1:24 PM EST
- YTD
- -29.83%
- 1 year
- -29.83%
5D -0.38 (-2.62%)
- Market cap
- 629.01M
- Revenue (ttm)
- 18.25M
- EPS (ttm)
- -2.69
- Shares out
- 47.40M
- YTD return
- -29.83%
- 1-year return
- -29.83%
- Volume
- 143.16K
- Avg volume
- 731.58K
- Open
- 13.98
- Previous close
- 14.26
- Day's range
- 12.82 – 14.00
- 52-week range
- 9.60 – 25.00
Key statistics
- 50-day average
- 18.91
- 200-day average
- 18.91
- Enterprise value
- 637.77M
- Price / sales
- 61.84
- Revenue growth
- 224.70%
- Total cash
- 207.88M
- Total debt
- 5.23M
Fundamental scorecard
4 of 25 checks passed on IAM’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iambic.ai
News
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Amer Sports, Sellas Life Sciences, Similarweb And Other Big Stocks Moving Higher On Tuesday Iambic Therapeutics Q3 EPS $(8.52) Misses $(0.72) Estimate, Sales $11.351M Miss $15.133M Estimate
Iambic Provides Business Updates and Third Quarter 2026 Financial Results Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35
Iambic Therapeutics Jumps 17% After-Hours as Wall Street Turns Bullish on Its AI-Powered Drug Discovery Platform
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
12 Health Care Stocks Moving In Monday's Intraday Session
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Your note
Sign in to keep a note on IAM — it syncs with the Stock Master app.
